These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 19133215)

  • 1. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of resistance and failure of treatment with maraviroc].
    Delgado R
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maraviroc efficacy in clinical studies on the development of the molecule].
    Moreno S; Hernández B; Gutiérrez C; Delsol E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of viral entry.
    Melby T; Westby M
    Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
    Hu Q; Huang X; Shattock RJ
    J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
    Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
    Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.